Juvenescence, which aims to increase its lifespan to 150 years shortly, raised $ 100 million in its latest fundraising campaign.
Founded in 2016, Juvenescence is the company that is creating an "ecosystem of longevity". With world-class scientists, pharmacologists, machine learning experts and skilled managers who can move confidently in this booming biotech sector.
The latest press release from the company announces a $ 10 million loan from its founders and another $ 10 million each for 4 other investors. These include Grok Ventures, Mike Cannon-Brookes' investment firm, and the private fund IPGL. The total collected by Juvenescence in the last 18 months is therefore $ 165 million, a figure that shows all the growth in interest in medical therapies aimed at longevity.
"Juvenescence has raised more funds than other similar companies, and it's good news for longevism. It's a reward for our team's skills. It makes us believe even more in the opportunities we're testing in collaboration with scientists, entrepreneurs and institutes of Research," says Jim mellon, one of the founders of Juvenescence.
"We have assembled a group of fantastic experts from around the world for our common mission to extend human life. As longevism becomes a familiar theme, we expect investor interest to increase. The next step is to go public with Juvenescence. to further accelerate its development. "
12 apostles of longevism: they will become 4 (or more) evangelists
The funds raised will be used to advance the various anti-aging programs, 12 of which are undergoing clinical trials. Of these, at least 4 will be on the market between 5 and 7 years from 2019.
Among them, many carry products that slow down cellular aging. Others reverse neurodegenerative processes or destroy senescent cells. Still others replace exhausted organs and edit patients' genes.
"The past six months have been really exciting for Juvenescence," says the CEO Dr. Greg Bailey. "Extraordinary medical and IT professionals have joined the team, they will help us bring our therapies to the public. This new injection of funds will give us the capital necessary to fully develop our first solutions."
Il longevism he gets more and more interest and money. The global anti-aging market is estimated at around $ 110 billion.